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genetic predispositions for BRCAx familial breast
cancer
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Background: Genetic predisposition is the primary risk factor for familial breast cancer. For the majority of familial
breast cancer, however, the genetic predispositions remain unknown. All newly identified predispositions occur
rarely in disease population, and the unknown genetic predispositions are estimated to reach up to total
thousands. Family unit is the basic structure of genetics. Because it is an autosomal dominant disease, individuals
with a history of familial breast cancer must carry the same genetic predisposition across generations. Therefore,
focusing on the cases in lineages of familial breast cancer, rather than pooled cases in disease population, is
expected to provide high probability to identify the genetic predisposition for each family.
Methods: In this study, we tested genetic predispositions by analyzing the family-specific variants in familial breast
cancer. Using exome sequencing, we analyzed three families and 22 probands with BRCAx (BRCA-negative) familial
breast cancer.
Results: We observed the presence of family-specific, novel, deleterious germline variants in each family. Of the
germline variants identified, many were shared between the disease-affected family members of the same family
but not found in different families, which have their own specific variants. Certain variants are putative deleterious
genetic predispositions damaging functionally important genes involved in DNA replication and damaging repair,
tumor suppression, signal transduction, and phosphorylation.
Conclusions: Our study demonstrates that the predispositions for many BRCAx familial breast cancer families can lie
in each disease family. The application of a family-focused approach has the potential to detect many new
predispositions.Background
Breast cancer is a leading cancer in women [1]. About
10-20% of breast cancer cases are family clustered, with
multiple family members affected by the disease [2].
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unless otherwise stated.disease. However, the genetic predispositions are currently
known for only 30-40% of the familial breast cancer dis-
ease families. The remaining 60-70% of women with fa-
milial breast cancer have unknown predispositions and
are diagnosed with BRCAx, for their unknown predis-
position of familial breast cancer [3]. It is estimated the
“missing” heredity trait for BRCAx families likely consists
of thousands of rare variants, each presenting a minor dis-
ease risk [4]. Indeed, broadly screening the variants across
disease populations has uncovered multiple new genetic
predispositions for familial breast cancer. A consistent pat-
tern among these newly classified predispositions is thatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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given disease population [5-10]. Their extreme rarity
implies that a greater sampling size of disease popula-
tions is required to identify the germline predispositions
[10]. However, such an expansion is deemed to increase
the complexity of data analysis, experimental costs, and
time needed. As such, focusing only on the rare variants
will not likely be able to determine the entire spectrum of
genetic predispositions for BRCAx familial breast cancer
families. New alternative hypotheses and approaches must
be explored to improve the situation. For example, mosaic
mutation has implications as potential predispositions for
familial breast cancer [11].
Familial breast cancer is defined as an autosomal
dominant genetic disease [12]. Although incidences of
breast cancer often exhibit atypical Mendelian patterns
due to the factors such as low penetrance of genetic
predispositions, the predisposition in a disease-prone
family is expected to transmit across generations and
shared between family members. Focusing on each dis-
ease family with a history of the disease is expected to
improve the chance to detect the predisposition in a
family compared to screening the disease population of
pooled cases without family relationships, which can
dilute the predisposition highly prevalent in a disease
family into insignificant level.
We hypothesize that the unknown predispositions for
many BRCAx familial breast cancer are specific to each
family with a history of the disease. Our previous exome
study of a BRCAx familial breast cancer family shows the
presence of rich genetic variants [13]. In the present study,
we expand the exome sequencing study by analyzing three
families with BRCAx familial breast cancer; 17 members
had cancer, and five members were without cancer. Our
study also includes 22 probands of BRCAx familial breast
cancer. Our study reveals the presence of family-specific,
novel, deleterious genetic variants as putative genetic pre-
dispositions in each family with BRCAx familial breast
cancer.
Methods
Use of human subjects
The use of the patient samples for the study was approved
by the Institutional Review Boards (IRB) of Creighton
University School of Medicine (#00-12265 ) and University
of Nebraska Medical Center (718-11-EP). All subjects
signed the Consent to Participate Form for cancer gen-
etic study.
Individuals from three families with BRCAx breast
cancer were used to generate exome sequences as we
have previously described [13]. Family I included six
individuals with breast cancer and two individuals
without breast cancer. Family II included five individ-
uals with breast cancer, one obligate carrier and twoindividuals without breast cancer. Family III included
five individuals with breast cancer and one individual
without breast cancer. Additionally, 22 probands for
BRCAx familial breast cancer were included in exome
sequencing. All cases used in the study were BRCA1-
negative, and BRCA2-negative, 41 were female and 3
were male, the average age is 42 years old (Figure 1,
Table 1).
Exome sequencing
For each sample, exome sequencing used DNA from blood
cells. Exome libraries were constructed using the TruSeq
Exome Enrichment Kit (62 Mb, Illumina, San Diego, CA)
as per manufacturer’s procedures. Exome sequences were
collected with a HiSeq™ 2000 sequencer (Illumina, San
Diego, CA) with paired-end (2 × 100). All exome data were
deposited in the Sequence Read Archive (SRA) database in
the National Center for Biotechnology Information (NCBI)
(Accession numbers SAMN02404413- SAMN02404456).
Exome sequence mapping and variant calling
Exome sequences were mapped to the human genome
reference sequence hg19 by Bowtie2 with default param-
eters in paired mode [14]. The subsequent SAM files
were converted to BAM files. Duplicates were removed
using Picard (http://picard.sourceforge.net). The mapped
reads were locally realigned using the genome mapping
tool RealignerTargetCreator from the Genome Atlas Tool
Kit (GATK) [15]. The base quality scores were recalibrated
using BaseRecalibrator (GATK), with NCBI dbSNP build
137, in the GATK resource bundles for reference sequence
hg19. VarScan 2 was used for variant calling, [16]. VarScan
2 was run on pileup data generated from BAM files using
SAMtools utilities [17]. The mpileup command, with –B
parameter to disable base alignment quality (BAQ) com-
putation, and the default parameters were used, with the
minimum read depth at 10 and the minimum base quality
at 30. The called variants were annotated with ANNOVAR
using the software-provided databases of the Reference Se-
quence (RefSeq; NCBI), dbSNP 137, the 1000 Genomes
Project, and the NIH Heart, Lung and Blood Institute
(NHLBI) Exome Sequencing Project (ESP) 6500 (http://
evs.gs.washington.edu).
Those that matched in the databases were classified as
known variants and removed. Family-specific normal
variants were eliminated by removing the variants
shared between the affected and the unaffected family
members in each family. The remaining novel variants
were classified into synonymous, non-synonymous, spli-
cing site change, stop gain- or loss groups. The variants
causing synonymous changes were then removed. For
the remaining variants, PolyPhen-2 was used to identify
variants causing deleterious effects in the affected genes
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Figure 1 Pedigrees of the three families used in the study. BC (breast cancer), Bt (brain tumor), CRC (colorectal cancer), Lu (lung cancer),
En (endometrium cancer), Ki (kidney cancer), Lym (lymphoma), NHL (non-Hodgkin lymphoma), OC (ovarian cancer), Pro (prostate cancer).
Sar (sarcoma), Sk (skin cancer).
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score: 18]. The variants defined as benign were removed.
These processes generated a list of novel, deleterious vari-
ants only present in the cancer-affected family members
and probands, Note that the variants in probands were
filtered by population databases only.Power calculation
Using a two-sided paired t-test and assuming a genetic
relative risk (GRR) equal to 5.8, disease prevalence equal
to 0.03, a disease locus frequency equal to 0.01, and a
sib recurrence ratio of 2, a sample size of 20 achieves
81% power to detect a mutation difference with a (stan-
dardized) effect size of 0.67 between the affected member
and the unaffected member. The significance level (alpha)
is, in turn, 0.05 [19,20].Validation
Sanger sequencing was used to validate deleterious vari-
ants. Sense and antisense PCR primers for each selected
variant were designed using the Primer3 program. The
original DNA samples that were used in exome sequen-
cing were served as PCR templates. PCR amplicons were
subjected to BigDye sequencing. The resulting sequences
were evaluated using CLC Genomics Workbench Program
(Cambridge, MA) to confirm the variants called from
exome sequences.
Results
Mapping exome data and calling variants
Exome sequences were collected via a blood sample
from each study participant and mapped to the human
genome reference sequence hg19. Variants were called
from the mapping data. We focused on single-base, non-
Table 1 BRCAx familial breast cancer cases used in the study
Family Cancer type Pathology BRCA1/2 Exome
Reads Bases Bases map rate (%) Coverage Variant called
Family 1
1 Breast Infiltrating ductal - 42,973,730 4,340,346,730 97.6 70 184,865
2 Breast Not available - 40,158,059 4,055,963,959 98.3 65 152,692
3 Breast Infiltrating ductal - 46,240,754 4,670,316,154 97.2 75 176,554
4 Prostate Adenocarcinoma - 23,418,595 2,365,278,095 98.1 38 207,103
5 No Cancer - 40,313,161 4,071,629,261 98.0 66 213,347
6 Breast, Colon Adenocarcinoma - 17,496,012 1,767,097,212 97.9 28 183,741
7 Brain Not available - 36,166,319 3,652,798,219 99.5 59 171,425
8 Breast Adenocarcinoma - 27,830,687 2,810,899,387 96.3 45 104,343
Family 2
1 Breast, Breast Medullary, infiltrating ductal - 33,419,098 3,375,328,898 92.9 54 113,079
2 Obligated carrier - 27,261,117 2,753,372,817 92.4 44 115,328
3 Breast Infiltrating ductal - 40,973,473 4,138,320,773 99.6 67 127,272
4 Breast Ductal carcinoma in situ - 29,561,523 2,985,713,823 91.5 48 108,655
5 Breast Infiltrating ductal - 25,790,969 2,604,887,869 93.1 42 84,687
6 Breast Infiltrating ductal - 37,657,589 3,803,416,489 91.6 61 139,891
7 No Cancer - 17,433,912 1,760,825,112 91.6 28 131,786
8 No Cancer - 35,977,512 3,633,728,712 97.3 59 128,680
Family 3
1 Endometrial Adenocarcinoma - 33,662,978 3,399,960,778 93.2 55 129,754
2 Breast, Skin Basal, infiltrating ductal - 29,648,460 2,994,494,460 98.3 48 198,862
3 No Cancer - 53,411,156 5,394,526,756 98.8 87 193,017
4 Breast Infiltrating ductal - 31,736,845 3,205,421,345 98.3 52 130,941
5 Breast Ductal carcinoma in situ - 35,014,538 3,536,468,338 98.4 57 129,754
6 Breast Not available - 38,418,769 3,880,295,669 97.5 62 161,953
Probands
1 Breast Ductal carcinoma in situ - 17,832,681 1,801,100,781 93.1 29 109,864
2 Breast Invasive ductal carcinoma - 36,166,319 3,652,798,219 99.5 59 142,155
3 Breast Invasive ductal carcinoma - 50,944,516 5,145,396,116 98.4 83 152,125
4 Breast Invasive ductal carcinoma - 43,889,986 4,432,888,586 99.6 71 169,633
5 Breast Invasive ductal carcinoma - 40,125,408 4,052,666,208 99.5 65 153,511
6 Breast Invasive lobular carcinoma - 31,798,628 3,211,661,428 97.5 52 119,875
7 Breast Invasive ductal carcinoma - 49,739,415 5,023,680,915 99.6 81 113,058
8 Breast Invasive ductal carcinoma - 63,352,269 6,398,579,169 99.6 103 99,732
9 Breast Invasive ductal carcinoma - 43,744,840 4,418,228,840 99.5 71 149,873
10 Breast Invasive ductal carcinoma - 43,573,311 4,400,904,411 99.6 71 141,236
11 Breast Invasive ductal carcinoma - 40,938,838 4,134,822,638 99.3 67 143,262
12 Breast Ductal carcinoma in situ - 36,258,870 3,662,145,870 99.6 59 138,018
13 Breast Ductal carcinoma in situ - 34,550,745 3,489,625,245 99.4 56 146,858
14 Breast Invasive ductal carcinoma - 50,295,200 5,079,815,200 99.5 82 156,666
15 Breast Invasive ductal carcinoma - 60,736,566 6,134,393,166 99.7 99 115,909
16 Breast Invasive ductal carcinoma - 57,383,360 5,795,719,360 99.6 93 120,945
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Table 1 BRCAx familial breast cancer cases used in the study (Continued)
17 Breast Invasive ductal carcinoma - 44,922,611 4,537,183,711 99.6 73 110,503
18 Breast Invasive ductal carcinoma - 33,883,509 3,422,234,409 99.4 55 131,955
19 Breast Invasive ductal carcinoma - 49,729,619 5,022,691,519 99.5 81 146,665
20 Breast Invasive ductal carcinoma - 63,184,143 6,381,598,443 99.6 103 119,680
21 Breast Invasive ductal carcinoma - 28,002,381 2,828,240,481 99.6 46 86,924
22 Breast Invasive ductal carcinoma - 47,794,798 4,827,274,598 99.5 78 112,030
Average 38,941,211 3,933,062,277 97.7 63 140,187
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and stop gain- or loss mutations, which are reliably detect-
able by exome analysis [21]. The average exome coverage
was 63x, and the average number of variants called was
140,187 per case (Table 1).
To increase the likelihood that the variants identified
in the breast cancer-affected family members are breast
cancer-associated, variants in each data set were filtered
by: 1) removal of common variants present in human
populations. All variants matching to population-derived
variant databases (i.e., dbSNP137, ESP6500, and 1000
genomes) were removed; 2) Removal of family-specific
normal variants. For the three families in the study, the
variants shared between the affected and the unaffected
members in the same family were removed. To identify
those causing deleterious effects in the affected genes, the
remaining variants were analyzed using the Polyphen-2
Program [18]. A total of 337 novel, deleterious variants
present only in the affected members of Families I, II, and
III were identified at an average of 112 variants per family
(Table 2, Additional files 1: Table S1A, B, C); 689 novel,
deleterious variants were identified in the 22 probands at
an average of 30 variants per proband (Table 2, Additional
files 2: Table S2A, B). Sanger sequencing validated the
mapped variants at a validation rate of 83% (53/64),
highlighting the reliability of the variants identified by
exome mapping analysis (Additional file 1: Table S1D).
Novel deleterious variants are mostly family-specific
We compared the variants within each family. We ob-
served that 25% of the variants on average (14% in
Family I, 29% in Family II, 35% in Family III) were
shared in multiple affected members in each family,
whereas 75% on average (86% in Family I, 71% in Family II
and 65% in Family III) were present only in single affected
member in each family (Table 2). We then compared
the shared variants between the three families, and
found only 1 variant was shared between Family I and
Family II, four variants were shared between Family I
and Family III (Figure 2A). For the 689 variants identi-
fied in the probands, 82% were proband-specific, and
only 18% were shared between probands at various fre-
quencies (Figure 2B, Additional file 2: Table S2A, S2B).The results indicate that the majority of the novel, dele-
terious variants identified in the three families and pro-
bands are family-specific, i.e., present only in each family
but not shared with other families.
Identification of putative genetic predispositions
We analyzed the shared mutations between the affected
members of the same family, the functional class of the
mutated genes, and existing evidence for their contribu-
tion to cancer. In doing so, we identified the variants as
the putative predispositions in Family I, II, and III, and
probands (Table 3, Additional file 1: Table S1A, S1B, S1C).
For Family I, this was the PTEN-Induced Putative Kinase 1
(PINK1); for Family II, these were Lysine (K) Acetyltransfer-
ase 6B (KAT6B) and Neurogenic Locus Notch Homolog
Protein 2 (NOTCH2); and for Family III, this was Phos-
phorylase Kinase Beta (PHKB).
PINK1 is a mitochondrial serine/threonine-protein
kinase. Mutation in PINK1 causes autosomal recessive
Parkinson’s disease [22]. KAT6B is a histone acetyl trans-
ferase involved in DNA replication, gene expression and
regulation, and epigenetic modification of chromosomal
structure [23]. Mutations in KAT6B cause multiple neuro-
logical diseases [24]. NOTCH2 is a member of the Notch
family involved in controlling cell fate decision. Low
Notch activity leads to hyperproliferative activity in breast
cancer [25] and mutation in NOTCH2 causes Hajdu-
Cheney syndrome [26]. PHKB regulates the function of
phosphorylase kinase [27]. Mutation in PHKB causes
glycogen storage disease type 9B [28]. Interestingly, a vari-
ant in Polymerase (DNA-Directed) Kappa (POLK) was
present in Family I member #4. POLK is a member of Y
family DNA polymerases, and functions by repairing
the replication fork passing through DNA lesions [29].
Although we are not able to validate it due to the lack
of DNA from the subject’s parents, it raises a possibility
that this variant could be a de novo mutation in this in-
dividual. Multiple transcriptional factors were also affected
by the mutations in each family. For example, the following
transcriptional factors were mutated in Family I: ZNF335,
LRRC66, ZNF417, ZNF587, GTF2I, ZFAND4, EIF4G2,
GZF1, CCDC86, ZSCAN18, ZNF546, TAF1L, and LRIG3
(Additional file 1: Table S1A).
Table 2 Novel, deleterious variants detected in breast
cancer-affected cases*
Family Total (%) Individual (%) Shared**(%)
Family 1
1 37 35 2
2 26 26 0
3 25 15 10
4 48 39 9
6 29 17 12
7 12 6 6
8 14 6 8
Subtotal 143 (199) 123 (86) 20 (14)
Family 2
1 22 13 9
2 15 5 10
3 21 9 12
4 21 12 9
5 16 8 8
6 8 2 6
Subtotal 66 (100) 47 (71) 19 (29)
Family 3
1 39 13 26
2 48 27 21
4 21 12 9
5 32 12 20
6 41 19 22
Subtotal 128 (100) 83 (65) 45 (35)
Total 337 (100) 253 (75) 84 (25)
Probands
1 35 10 25
2 58 22 36
3 74 28 46
4 77 49 28
5 70 28 42
6 41 16 25
7 31 24 7
8 43 27 16
9 51 19 32
10 61 30 31
11 70 35 35
12 51 12 39
13 55 15 40
14 60 30 30
15 51 31 20
16 41 31 10
17 32 18 14
Table 2 Novel, deleterious variants detected in breast
cancer-affected cases* (Continued)
18 57 25 32
19 58 18 40
20 47 23 24
21 33 25 8
22 34 22 12
Total 689 (100) 568 (82) 121 (18)
Per proband 30 26 6
*The counts in subtotal and total are the unique number of variants.
**Shared with family members in the families, or shared with other probands.
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as those of the three families (Table 3). In the 22 probands,
four carried variants affecting the genes involved in DNA
replication and damaging repair. Those include Polymer-
ase (DNA-directed) Theta (POLQ) in Proband #2, RAD23
Homolog B (S. cerevisiae) (RAD23B) in Proband #3, LigaseA
B
Figure 2 Comparison of the variants in BRCAx families and
probands. A. Comparison in the three families. B. Comparison in
the probands. The results show that the variants detected in the
cancer-affected family members are highly family-specific. The higher
rate (18%) of the shared variants in the probands are likely due to
the remaining normal variants not filtered in the probands and the
larger number of families represented by the probands than the
three families.
Table 3 Putative predispositions in familial breast cancer families and probands







Family 1 1 2 3 4 6 7 8
GPRIN1 G protein regulated
inducer of neurite
outgrowth 1
chr5:176026123 c.T713C p.L238S Exonic 0.91 D - + + + + + - 5
PINK1 PTEN induced
putative kinase 1
chr1:20972051 c.960-2A > G Splicing NA NA - - + + - - - 2
POLK Polymerase (DNA
directed) kappa
chr5:74892737 c.A2219G p.H740R Exonic 0.62 P - - - + - - - 1
Family 2 1 2 3 4 5 6
KAT6B K(lysine)
acetyltransferase 6B
chr10:76789128 c.G4546T p.D1516Y Exonic 0.95 D - + + + + + 5
KAT6B K(lysine)
acetyltransferase 6B
chr10:76789311 c.C4729T p.R1577C Exonic 0.96 D - + + + + + 5
NOTCH2 Notch 2 chr1:120459167 c.C6178T p.R2060C Exonic 0.99 D - - + - - + 2
Family 3 1 2 4 5 6
NANP N-acetylneuraminic
acid phosphatase





Splicing NA NA - + - + - 2
Proband
1 JAKMIP3 Janus kinase and
microtubule
interacting protein 3
chr10:133955524 c.G1574C p.G525A Exonic 1.00 D
2 POLQ Polymerase (DNA
directed), theta
chr3:121207798 c.A3980C p.Q1327P Exonic 1.00 D
3 DUX2 Double homeobox 2 chr10:135494906 Splicing NA NA
4 UBE2L3 Ubiquitin-conjugating
enzyme E2L 3
chr22:21975938 c.G349A p.E117K Exonic 0.96 D . .
5 RAD23B RAD23 homolog B
(S. cerevisiae)
chr9:110087260 c.C1028T p.P343L Exonic 0.99 D . .
7 GATA3 GATA binding protein 3 chr10:8100630 c.C604T p.R202C Exonic 0.92 D
8 KAT6B K(lysine)
acetyltransferase 6B
chr10:76744854 c.G2390A p.S797N Exonic 0.98 D
9 LIG1 Ligase I, DNA,
ATP-dependent
chr19:48637322 c.G1525A p.E509K Exonic 0.95 D . .
10 LIG4 Ligase IV, DNA,
ATP-dependent
chr13:108862463 c.G1154A p.R385K Exonic 1.00 D
14 NOTCH2 Notch 2 chr1:120529603 c.G854A p.R285H Exonic 1.00 D
15 ABL1 c-abl oncogene 1,
non-receptor tyrosine
kinase
chr9:133729493 c.G122A p.G41D Exonic 0.92 D
16 TNK2 Tyrosine kinase,
non-receptor, 2
chr3:195596385 c.C1760T p.P587L Exonic 1.00 D
17 NFRKB Nuclear factor related to
kappaB binding protein
chr11:129755398 c.G611A p.R204H Exonic 1.00 D
18 NFKBIZ Nuclear factor of kappa
light polypeptide gene
enhancer
chr3:101576029 Splicing NA NA
Wen et al. BMC Cancer 2014, 14:470 Page 7 of 11
http://www.biomedcentral.com/1471-2407/14/470
Table 3 Putative predispositions in familial breast cancer families and probands (Continued)
19 SMG1 SMG1 phosphatidylinositol
3-kinase-related kinase
chr16:18879624 c.C3083T p.T1028M Exonic 0.99 D
20 PRKCQ Protein kinase C, theta chr10:6528042 c.G855C p.Q285H Exonic 1.00 D
21 ADRA2A Adrenoceptor alpha 2A chr10:112838117 c.C363G p.C121W Exonic 1.00 D
22 PPFIA4 Protein tyrosine
phosphatase, receptor
type
chr1:203025582 c.C668T p.T223M Exonic 0.92 D
D: Probably damaging (score: 0.909-1); P: Possibly damaging (score: 0.447 - 0.908).
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Ligase IV DNA, ATP-dependent (LIG4) in Proband #10.
POLQ repairs the apurinic sites [30]. RAD23B plays a role
in nucleotide excision repair [31]. LIG1 ligates nascent
DNA of the lagging strand, and a mutation in LIG1 causes
replication errors, genome instability, and cancer [32].
LIG4 catalyzes double-strand break repair by joining
non-homologous ends, and mutation in LIG4 causes
LIG4 syndrome [33]. Several variants are found in well-
known oncogenes and tumor suppressor genes, such as
GATA Binding Protein 3 (GATA3) in Proband #7 and
Abelson Murine Leukemia Viral Oncogene Homolog 1
(ABL1) in Proband #18. GATA3 regulates luminal epithe-
lial cell differentiation in the mammary gland [34,35]. The
abnormal expression of GATA3 causes luminal A-type
breast cancer [36-38]. ABL1 is a tyrosine kinase that
controls cell differentiation and division. It is involved
in (9, 22) translocation, forming BCR-ABL fusion gene
in chronic myelogenous leukemia (CML) [39]. Several
individual variants in different cases affect the same genes
but at different positions. For example, in Proband #8, a
variant in KAT6B (c.G1841A/p.S614N) affects the HAT do-
main at the N terminal, whereas two variants in KAT6B in
Family II (c.G3997T/p.D1333Y and c.C4180T/p.R1394C)
affect the Met-rich domain at the C-terminal. In Proband
#14 and Family II, two different NOTCH2 variants (c.
G854A/p.R285H, c.C6178T/p.R2060C) were present.
Multiple variants affect the genes involved in phosphoryl-
ation. These include Tyrosine Kinase Non-Receptor 2
(TNK2) in proband #16, Phosphatidylinositol 3 Kinase-
Related Kinase (SMG1) in Proband #19, Protein Kinase C
Theta (PRKCQ) in Proband #20, and Protein Tyrosine
Phosphatase, Receptor Type F (PPFIZ4) in Proband #22.
We also performed an analysis at the pathway level by
annotating the mutation-affected genes in the three fam-
ilies using KEGG database (http://www.genome.jp/kegg/
pathway.html). Certain mutations were identified to affect
several functional pathways. For example, the genes
mutated in Family I (ACADVL, AHCY, ALDOA, SGPL1,
MAT1A, GALNT8, GGT1) are involved in metabolic
pathways. The genes mutated in Family 2 (NOTCH2,
DUSP16) are involved in Notch signaling pathway and
MAPK signaling pathway; genes mutated in Family III(SLC9A1, ITGAX, ITGAD) are involved in regulation of
actin cytoskeleton.Discussion
The majority of families with familial breast cancer lack
evidence for their genetic predispositions. Efforts in past
decade have made slow progress in determining the un-
known genetic predispositions. Currently, population-
based approach is adapted as the major promising tool
to reach the goal [40]. One weakness of this approach is
that it can “dilute out the effects of a very strong associ-
ation in a small subset of the study population” [41]. It
requires a large-size disease population of over tens of
thousands but the predispositions identified will likely
remain very rare in the disease population. Due to the
extreme rarity, such genetic predispositions are often
difficult to confirm in different disease populations and
to distinguish from normal polymorphisms [5,10]. Our
study observed the presence of family-specific, novel,
deleterious variants, and putative predispositions in the
families and probands analyzed. The information im-
plies that, in addition to the population-based approach,
a family-based approach provides another option to de-
termine the genetic predisposition.
Based on the higher frequencies of well-known predispo-
sitions identified by traditional approaches, the rarity of the
predispositions recently identified by population-based ap-
proach, and the presence of family-specific, novel, deleteri-
ous variants in disease families revealed in our study, we
propose a model to explain the genetic predispositions in
familial breast cancer (Figure 3). In this model, the predis-
position in BRCA1 has the highest frequency in the famil-
ial breast cancer population, other known predispositions
gradually decrease their frequencies to insignificant levels,
and the predispositions for many BRCAx familial breast
cancers are family-specific. The model explains the diffi-
culty in using traditional and population-based approaches
to determine the unknown predispositions, and highlights
that applying family-focused approach will be able to de-
termine the genetic predispositions for many BRCAx dis-
ease families. This model can be further tested in larger










Figure 3 A model for the genetic predispositions in familial breast cancer. The known predisposition in BRCA1 has the highest sharing
frequency in the disease population, other known predispositions decrease their frequencies towards extreme rarity in the disease populations,
and the family-specific predispositions are enriched in many disease families without known predispositions. The biggest circle represents the
entire genetic predispositions in familial breast cancer. The open circles represent the shared, known predispositions, and the black circles
represent the family-specific predispositions.
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tations present, rather than reach for comprehensive cover-
age of germline mutations in each family. We achieved this
by eliminating all variants matched in population-derived
variant databases (i.e., dbSNP137, ESP6500, 1000 genomes)
to maximally avoid the variants representing normal poly-
morphism. Inclusion of such variants as the predisposition
candidates, even with the use of certain cut-off such as
minor allele frequency (MAF) <0.01, can increase the sensi-
tivity but decrease the specificity of the variants referred to
as putative predispositions.
Assignment of a specific mutation as a true predispos-
ition to a disease family requires solid phenotypic evidence
from in vitro analysis, cell line tests, search of the literature,
bioinformatics data analysis, and animal models. This is
best evidenced by determining the BRCA1 germline muta-
tions as genetic predispositions in breast cancer, in which
the definitive conclusion for its contribution to breast can-
cer is based on the mouse models showing development of
breast cancer with the germline mutated BRCA1 [42]. Our
current study aims to provide evidence that the BRCAx
disease families are enriched with germline damaging mu-
tations, such that focusing on each disease family will berequired to determine the genetic predisposition in each
family. Indeed, even under strict mapping conditions,
large numbers of mutations have been detected in each
disease family and probands. While the data provide rich
resources to identify the true predisposition for the disease
family, the data cannot be considered as true predispos-
ition without further phenotypic and functional evidences.
Conclusions
Our study shows that genetic predispositions in many
BRCAx familial breast cancer families can be family-specific.
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